The evidence that mGlu2 receptors negatively regulate responses mediated by 5-HT2A receptors17, 18 paved the way for the development of mGlu2/3 receptor agonists or mGlu2 receptor positive allosteric modulators (PAMs) in the treatment of schizophrenia. Here, GRM2 is linked to schizophrenia.